ASAS Keeps Bone Marrow Oedema at the Center of MRI Classification for Axial Spondyloarthritis
The ASAS MRI working group has updated how radiologists and rheumatologists should think about a positive MRI in axial spondyloarthritis, and the core message is deliberately conservative. Active sacroiliitis remains the defining imaging feature, with bone marrow oedema in subchondral bone continuing to carry the decisive weight for classification.
The update does not dilute the original concept. It sharpens it.
Why the 2009 Definition Needed a Fresh Pass
The group set out to review the wording of the existing MRI definition used in the classification criteria for axial SpA after new data accumulated since the original 2009 version entered print. The process was not a single-methodology exercise; it was a consensus review built around existing definitions, newer evidence relevant to the MRI diagnosis and classification of sacroiliitis and spondylitis, and then a formal presentation of a draft proposal to the ASAS membership for voting.
That sequence matters because MRI interpretation in axial spondyloarthritis sits in a difficult zone between specificity and overcalling disease. Too loose a definition risks labeling mechanical or incidental sacroiliac changes as inflammatory disease. Too strict a definition risks missing patients whose early inflammatory lesions are subtle, patchy, or not yet accompanied by obvious structural injury. The updated wording attempts to hold that line without expanding the threshold beyond what current evidence can support.
Active Sacroiliitis Still Means Marrow Edema in the Right Place
The clearest finding from the consensus update is the continued primacy of bone marrow oedema on MRI in the subchondral bone. That lesion remains the defining observation for active sacroiliitis. In practical terms, the presence of inflammatory signal in the sacroiliac joint still anchors the classification concept of a positive MRI in axial SpA.
Structural lesions seen on MRI can support the reading. They may help an observer decide whether the inflammatory signal is genuinely part of the spondyloarthritis spectrum rather than a nonspecific or mechanically induced change. But structural damage is not required to satisfy the definition. The center of gravity remains on active inflammation, not chronic remodeling.
This choice reflects the biology of the disease. Axial spondyloarthritis begins with inflammatory activity in the sacroiliac joints, and MRI is most useful when it captures that active process before irreversible structural change becomes obvious. Bone marrow oedema is the imaging expression of that inflammatory state, which is why it remains the most defensible feature for classification purposes.
Structural Damage Can Inform the Read, But It Does Not Define It
The update gives structural injury a supporting role rather than a leading one. Erosions, sclerosis, fat metaplasia, or other structural changes may increase confidence in the diagnosis when viewed alongside inflammatory lesions, but they are not mandatory for a positive MRI classification result. That distinction is clinically important because it preserves sensitivity for earlier disease while acknowledging that chronic changes can strengthen the diagnostic narrative.
A single imaging feature should not be forced to do two jobs at once. Inflammatory activity and structural injury are related, but they are not interchangeable.
The revised document also adds guidelines and images to help clinicians apply the definition more consistently. That kind of clarification often sounds modest, yet in MRI-based classification it can be decisive. Readers need common visual standards, especially when borderline lesions sit near the threshold between abnormal and normal variation. Without that shared framework, different observers can reach different conclusions from similar scans.
The Update Reinforces Classification, Not a Standalone Diagnostic Shortcut
The language in this update remains framed around classification of axial SpA rather than a claim that MRI alone can settle every diagnostic question. Classification criteria are designed to create a consistent research and clinical framework, and MRI contributes to that framework by identifying active sacroiliitis with sufficient specificity. The working group’s approach respects that boundary.
This restraint is clinically sensible. Sacroiliac MRI findings exist on a spectrum, and the challenge is not simply detecting any abnormality but deciding whether the abnormality fits inflammatory disease. The addition of guidance and images suggests a desire to reduce ambiguity at the margins, where readers may see mild edema, limited lesion distribution, or mixed inflammatory and structural signals.
For clinicians, the message is straightforward: the MRI definition for axial SpA still hinges on active inflammatory change, especially subchondral bone marrow oedema, and structural lesions serve as contextual support rather than a required criterion. That approach preserves the original intent of the classification system and avoids inflating the importance of chronic damage before evidence is ready to justify it.
Why the Spine Waits Its Turn
The conclusion also makes clear that more data are still needed on MRI features of structural damage in the sacroiliac joint and on MRI features in the spine before those findings can be assigned a larger role in classification. The current update therefore does not extend the definition beyond sacroiliac inflammation, even though spinal imaging abnormalities are relevant to the broader disease phenotype.
That restraint reflects the current evidence base. The sacroiliac joints remain the most established imaging target for classification, and the working group stopped short of expanding the definition into a broader structural model without stronger data. In other words, the update chooses the most reproducible signal rather than a more expansive but less certain one.
For patients, the practical consequence is that a negative or equivocal scan without clear active sacroiliitis still cannot be converted into a positive classification result simply because chronic structural abnormalities are present. For radiologists, the instruction is to keep the focus on inflammatory activity and to use the supporting features as aids to interpretation, not as substitutes for the central lesion.
What This Means for MRI Readers at the Bedside
The new wording should make the reading room a little less ambiguous. MRI in axial spondyloarthritis is most useful when the reader can identify active sacroiliitis with confidence, and the update confirms that confidence still rests on a fairly narrow imaging foundation. Bone marrow oedema in the subchondral bone remains the hallmark. Structural lesions may increase certainty, but they do not replace the active lesion that first defined the entity.
That approach reflects a broader principle in rheumatologic imaging: classification improves when the imaging definition is anchored to reproducible inflammatory biology rather than to late consequences of disease. The updated ASAS guidance keeps that principle intact while giving clinicians more help in applying it consistently.
The unresolved issue is not whether structural damage matters at all. It clearly does. The remaining question is how much weight future data will justify assigning to sacroiliac damage patterns and spinal MRI features when classification criteria are revisited again. Until then, active sacroiliitis remains the standard, and bone marrow oedema remains the imaging feature that carries the classification decision.